Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jan;21(1):12-26.
doi: 10.1177/1078345814557513.

Validation of a Brief Measure of Opioid Dependence: The Rapid Opioid Dependence Screen (RODS)

Jeffrey A Wickersham  1 , Marwan M Azar  2 , Christopher M Cannon  3 , Frederick L Altice  4 , Sandra A Springer  2
Affiliations

Validation of a Brief Measure of Opioid Dependence: The Rapid Opioid Dependence Screen (RODS)

Jeffrey A Wickersham et al. J Correct Health Care. 2015 Jan.

Erratum in

Abstract

The Rapid Opioid Dependence Screen (RODS) is an 8-item measure of opioid dependence designed for quick, targeted screening in clinical and research settings. Based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth edition, criteria, the RODS has an average administration of less than 2 minutes and can easily be administered as a stand-alone instrument or as part of a comprehensive interview. This study reports on the initial validation of the RODS among a sample of 97 newly incarcerated, HIV-positive individuals. Using the Mini International Neuropsychiatric Interview as the primary measure of opioid dependence, the RODS showed good-to-strong sensitivity (.97), specificity (.76), positive predictive value (.69), and negative predictive value (.98), while concordance analysis revealed moderate diagnostic agreement (κ = .67). Psychometric properties revealed strong internal consistency (α = .92) and inter-item correlations (.66 to .87).

Keywords: instrument; measurement; opiates; opioids; screen; substance dependence.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests

The authors disclosed the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Frederick L. Altice: speaker honorarium from Bristol-Myers Squibb, Gilead Sciences, Merck, and RUSH Simply Speaking; research support from Gilead Sciences. For information about JCHC’s disclosure policy, please see the Self-Study Exam.

References

    1. Alistar SS, Owens DK, Brandeau ML. Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: A modeling analysis for Ukraine. PLoS Medicine. 2011;8:e1000423. doi: 10.1371/journal.pmed.1000423. - DOI - PMC - PubMed
    1. Altice FL, Bruce RD, Lucas GM, Lum PJ, Korthuis PT, Flanigan TP BHIVES Collaborative. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: Results from a multisite study. Journal of Acquired Immune Deficiency Syndromes. 2011;56:S22–S32. doi: 10.1097/QAI.0b013e318209751e. - DOI - PMC - PubMed
    1. Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet. 2010;376:59–79. doi: 10.1016/S0140-6736(10)60829-X. - DOI - PMC - PubMed
    1. Altice FL, Sullivan LE, Smith-Rohrberg D, Basu S, Stancliff S, Eldred L. The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention. Clinical Infectious Diseases. 2006;43:S178–S183. doi: 10.1086/508181. CID40075 [pii] - DOI - PubMed
    1. Basu S, Smith-Rohrberg D, Bruce RD, Altice FL. Models for integrating buprenorphine therapy into the primary HIV care setting. Clinical Infectious Diseases. 2006;42:716–721. doi: 10.1086/500200. - DOI - PubMed

Publication types